Sutro Biopharma Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Sutro Biopharma, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Revenue & Gross Profit
Revenue62.04153.7367.7761.8842.7242.74
Cost of Revenue7.2211.8310.11104.4076.960.00
Gross Profit54.83153.7357.67-42.52-34.2442.74
Operating Expenses
Research & Development252.04180.43127.07104.4076.9665.61
Selling, General & Administrative48.4562.5859.5456.0036.8232.59
Operating Expenses293.28243.01186.6156.0036.8298.20
Operating Income-238.45-89.28-128.94-98.52-71.06-55.47
Other Income/Expense
Interest Income44.4314.513.460.581.510.00
Interest Expense31.0723.75-7.42-3.20-2.800.00
Other Income/Expense13.36-24.4312.130.06-1.17-4.07
Income
Income Before Tax-225.10-88.60-116.70-105.54-32.03-51.39
Income Tax Expense2.3618.202.500.000.100.00
Net Income-227.46-106.79-119.20-105.54-32.13-55.74
Net Income - Continuous Operations-227.46-106.79-119.20-105.540.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.00
EBITDA-180.45-81.79-123.25-93.68-66.76-46.97
EBIT-225.06-88.59-128.94-98.52-71.06-50.29
Depreciation & Amortization7.226.805.694.844.300.00
Earnings Per Share
Basic EPS-30.00-2.00-23.00-23.00-10.00-2.00
Diluted EPS-30.00-2.00-23.00-23.00-10.00-2.00
Basic Shares Outstanding7.6860.165.074.613.2622.96
Diluted Shares Outstanding7.6860.165.074.613.2622.96